Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 May 28;16(6):965-966.
doi: 10.1021/acsmedchemlett.5c00284. eCollection 2025 Jun 12.

Deuterated 1,3 Dihydro‑2 H‑indole-2-one Derivatives for Treatment of Depression or Anxiety

Qi-Long Hu  1 , Steven H Liang  1
Affiliations
Editorial

Deuterated 1,3 Dihydro‑2 H‑indole-2-one Derivatives for Treatment of Depression or Anxiety

Qi-Long Hu et al. ACS Med Chem Lett. .

Abstract

This patent application discloses a series of l,3-dihydro-2H-indol-2-one derivatives targeting the vasopressin 1b receptor (V1b) or both the V1a and V1b receptors, as represented by Formula I. These vasopressin receptor antagonists exhibit significant therapeutic potential, particularly for the treatment of depression or anxiety, and hold promises for benefiting patients with reduced dosing frequency.

PubMed Disclaimer

References

    1. Ślusarz M. J.. Structural Basis for Antagonist Binding to Vasopressin V1b Receptor Revealed by the Molecular Dynamics Simulations. Biopolymers. 2025;116(1):e23627. doi: 10.1002/bip.23627. - DOI - PubMed
    1. Guan W., Qi W., Sheng X. M.. Evidence for the Contribution of Vasopressin V1B Receptors in the Pathophysiology of Depression. Biochem. Pharmacol. 2025;231:116672. doi: 10.1016/j.bcp.2024.116672. - DOI - PubMed
    1. Hu H., Zarate C. A. Jr., Verbalis J.. Arginine Vasopressin in Mood Disorders: A Potential Biomarker of Disease Pathology and A Target for Pharmacologic Intervention. Psychiatry Clin. Neurosci. 2024;78(9):495–506. doi: 10.1111/pcn.13703. - DOI - PMC - PubMed
    1. Kanes S. J., Dennie L., Perera P.. Targeting the Arginine Vasopressin V1b Receptor System and Stress Response in Depression and Other Neuropsychiatric Disorders. Neuropsychiatr. Dis. Treat. 2023;19:811–828. doi: 10.2147/NDT.S402831. - DOI - PMC - PubMed
    1. Chaki S.. Vasopressin V1B Receptor Antagonists as Potential Antidepressants. Int. J. Neuropsychopharmacol. 2021;24(6):450–463. doi: 10.1093/ijnp/pyab013. - DOI - PMC - PubMed

Publication types

LinkOut - more resources